These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 30036146)

  • 1. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

  • 5. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
    Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
    J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 17. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Tomić I; Pavić M
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
    Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
    Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
    Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
    Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.